anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The most frequent type of adverse reaction occurring with Ibuprofen Tablets are gastrointestinal. In controlled clinical trials the percentage of patients reporting one or more gastrointestinal complaints ranged from 4% to 16%.

In controlled studies when Ibuprofen Tablets were compared to aspirin and indomethacin in equally effective doses, the overall incidence of gastrointestinal complaints was about half that seen in either the aspirin- or indomethacin-treated patients.

Adverse reactions observed during controlled clinical trials at an incidence greater than 1% are listed in the table. Those reactions listed in Column one encompass observations in approximately 3,000 patients. More than 500 of these patients were treated for periods of at least 54 weeks.

Still other reactions occurring less frequently than 1 in 100 were reported in controlled clinical trials and from marketing experience. These reactions have been divided into two categories: Column two of the table lists reactions with therapy with Ibuprofen Tablets where the probability of a causal relationship exists: for the reactions in Column three, a causal relationship with Ibuprofen Tablets has not been established.

Reported side effects were higher at doses of 3200 mg/day than at doses of 2400 mg or less per day in clinical trials of patients with rheumatoid arthritis. The increases in incidence were slight and still within the ranges reported in the table.
Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
BMS patients will be classified into the primary type and secondary type according to the patients' clinical histories and laboratory examinations. The secondary BMS only includes nutritional deficiency, such as Vitamin B12, folate, iron, zinc. At first, the primary BMS patients are treated with 0.5\~1 mg clonazepam every day before sleep for 8 weeks. The secondary BMS patients are treated with vitamin B12, folate, iron and zinc according to the patient's nutritional deficiency status. Patients with no improvement or little improvement after the first stage of Western medicine management will be arranged to receive traditional Chinese medicine (TCM) therapy. All patients will receive the TCM model, including TCM doctor, automatic tongue diagnostic system (ATDS), and body constitutional questionnaire (BCQ), evaluations.

The results of this study are expected to understand whether adjuvant TCM treatment of BMS can improve treatment efficacy. The investigators will understand whether the constitution pattern may be a predictive indicator of efficacy for western BMS. The investigators will find a diagnostic indicator for the TCM model and apply it to the assessment of the prognosis of BMS patients.
The embodiments of the invention described herein employ sophisticated techniques for managing distributed processes in a process automation system. Specifically, one embodiment of the invention implements a general purpose property mechanism in which arbitrary data is attached to any object in the system (e.g., projects, procedures, jobs, job steps, resources, etc), thereby providing a convenient way to configure the system without modifying the underlying program code. In addition, in one embodiment, a three-tier hierarchy of data object is employed: 'projects,' 'procedures,' and 'steps' (or 'projects,' 'jobs' and 'job steps' during runtime). A property may be attached to any object on any tier of the hierarchy to configure that object and (potentially) all of the objects which reference the property. The properties and property sheets may be attached both statically (before runtime) and dynamically (during runtime). Moreover, one embodiment of the invention employs a unique property substitution syntax to allow the value for a particular property to be located and substituted dynamically at runtime. In addition, advanced report generation techniques are described below in which the report generation process is logically separated into a data gathering stage and a report generation stage. The data gathering stage extracts certain specified properties and diagnostic information from each job step. The extracted information is then stored in a highly flexible, reusable data format which is used to create different types of user- configurable reports.
The present invention relates to the field of biomedicines. Disclosed are a polypeptide having an immune check-point antagonistic activity for a human programmed death ligand 1 (PD-L1), and an application thereof. A series of polypeptides in the present invention each comprise an amino acid sequence 1. SNGLSQPV; and 2. KCAAFSNGLSQPVCD(C-C), or a pharmaceutically acceptable salt thereof. Specifically, the polypeptide can implement specific recognition of PD-L1 on the surface of a cell and mediate specific killing of cells in which PD-L1 is positive, and can also block an immunosuppression signal pathway of PD-1/PD-L1 and eliminate the immunosuppression effect of tumors, thereby achieving a specific killing effect.
PURPOSE:To obtain glycine tablet having uniform composition and free from disintegration, chipping, capping and lamination phenomena, by coating glycine powder or glycine-containing granules with a polymer, and tableting the coated product by direct powder compression process. CONSTITUTION:Glycine powder or glycine-containing granules obtained by the granulation of a mixture of glycine powder, a diluent and a binder, are coated with a water-soluble polymer (e.g. dextrin, gelatin, etc.) or a water-insoluble polymer (e.g. cellulosic polymer, acrylic acid polymer, etc.). The coated glycine powder or granules are mixed with additives (usually powder passing through a 30 mesh sieve) selected from sugars, electrolytes, vitamins, mineral salts, buffering agents, diluents, and active components, and the mixture is tableted. The amount of the coating agent is preferably <=30wt%, especially 2-10wt% of glycine.
Up to three Diode and Radio Frequency treatments and up to three additional radio frequency treatments will be performed per patient at the discretion of the principal investigator. Diode treatments will be spaced six weeks apart while the radio frequency treatments will be spaced between 2-3 weeks apart.
Provided here are new ophthalmologically suitable pharmaceutical compositions comprising an effective amount of a moxifloxacin compound and an effective amount of a triamcinolone compound. In aspects, the compositions are stable suspensions, which maintain physical stability and chemical stability for extended periods of time (e.g., exhibiting no sustained flocculation, coagulation, or clumping after several months of storage under typical storage conditions). In aspects, the compositions are suspensions that include a suspension component comprising one or more suspension agents. In aspects, the suspension component includes an ionic suspension agent. In aspects, the composition also or alternatively comprises a non-ionic surfactant, non-ionic suspension agent, or both, or an agent that provides both functions. In aspects, such compositions further comprise an effective amount of a chelating agent/component. Further described are related compositions and methods of making and using such compositions, e.g., in the treatment of eye infections.
The invention relates to medicine, in particular to neurology and psychiatry and can be used in the form of an agent for normalising the physiological and functional activity of the central nervous system of a brain intellectually-mnestic function. The inventive medicinal agent exhibits a nootropic activity an comprises dimephosphone in the form of an active substance. Said medicinal agent is embodied in the form of an aqueous solution and also comprises citric acid and lithium carbonate at the following component ratio: 5.0-30.0 mass% dimephosphone, 0.5-5.0 mass % lithium carbonate, 3.0-4.0 mass % citric acid, the rest up to 100% being deionised water. The medicinal agent in the form of a syrup has the following component ratio: 3.0-5.0 mass% dimephosphone, 1.0-1.2 mass% lithium carbonate, 4.0-5.0 mass% citric acid and 89-92.0 mass% sixty-four percentage sugar syrup. A syrup having a high concentration of dimephosphone and a glycerin-containing syrup are also disclosed as the variants of the invention. Said medicinal agents have more physiological pH values exhibited within an extended range of concentrations, are  characterized by  the high dilution stability of the solutions thereof and have a delectable flavor, thereby easing the use thereof in a child treatment form.
The anti-atherogenic effect of tirzepatide has been studied in preclinical studies and seems to involve mechanisms related to a reduction in vascular inflammation and lipid accumulation. Any direct anti-atherogenic effect of tirzepatide may potentially reduce the incidence of major cardiovascular endpoints in individuals with overweight or obesity. As a proof of principle, it would be of scientific and clinical interest to explore the anti-atherogenic effect of tirzepatide in humans. IVUS-NIRS imaging is uniquely suited for this purpose, as it makes it possible to detect changes in not only atheroma burden by IVUS but also to detect progression within the plaques in the lipidic/necrotic core component by NIRS. LCBItotal allows for consecutive detection of small changes in the same individual, which is pivotal to explore the supposed antiatherogenic mechanism of tirzepatide with enough statistical power.

The investigators hypothesize that once-weekly sc. tirzepatide can reduce coronary lipid accumulation in the arterial wall and the progression of atheromatosis in individuals with overweight or obesity and established high-risk atherosclerosis. The investigators aim to investigate this hypothesis in a proof-of-principle study by investigating the change in coronary plaque composition in individuals with overweight or obesity and coronary artery disease (CAD) with high-risk characteristics by NIRS imaging randomised to 52-week treatment with tirzepatide or placebo.
Mdm2 binds to p53 in cells in which mdm2 is not overexpressed, i.e. in cells in which mdm2 is expressed at normal or low levels, and this interaction targets p53 for degradation. The present invention exploits this mechanism of p53 degradation to stabilise a substance comprising a mdm2 binding domain linked to a coupling partner in cells in which this mdm2 mediated degradation pathway does not operate efficiently. In contrast, in normal cells expressing functional mdm2, the substance will tend to be unstable as it will be marked for degradation through the interaction of the endogenous mdm2 with the mdm2 binding domain of the substance. Accordingly, the substances can be used to deliver the coupling partner to such cells, e.g. for use in the diagnosis and/or treatment of cancer, viral infections or other conditions associated with non functional p53 or mdm2.
Tracheal stenosis is a serious complication following prolonged intubation. Two types of tracheal stenosis; Glottic and subglottic stenoses have common features in that they are challenging in terms of ventilation, oxygenation and intubation. However, there are important differences in the challenges of airway managementA thinner tube may be sufficient to overcome the airway difficulty in glottic stenoses. However, in subglottic tracheal stenosis, a thinner tube may not be conveyed to the distal of the stenosis. As a result, adequate ventilation and oxygenation may not be provided with an intubation tube placed proximal to the trachea. This study consists of our anesthesia management experience in patients with unusual placement of tracheal stenosis due to Covid-19 undergoing tracheal dilatation.
A compound represented by general formula (M) or a pharmaceutically acceptable salt of the same is a cortistatin A analog which preserves the bioactivity of cortistatin A, has a simple chemical structure that can be supplied in large volumes by means of chemosynthesis, and can be used as an active component of cancer prevention or treatment drugs. (In the formula: R 1  represents a substituted or un-substituted aromatic heterocyclic group. R 2  represents a hydrogen atom, a substituted or un-substituted 1-3 carbon number alkyl group, OR 3  group, N (R 3 ) 2  group, C (=O) OR 3  group, or C (=O) N (R 3 ) 2  group. R 3  represents a hydrogen atom, a 1-4 carbon number alkyl group or a 1-4 carbon number acyl group. R 4  represents a hydrogen atom, an oxygen atom, or an OR 5  group. R 5  represents a hydrogen atom, a 1-3 carbon number alkyl group or a 1-3 carbon number acyl group.)
BACKGROUND: Pannexin1 (Panx1) is a membrane channel expressed in different cells of the nervous system and is involved in several pathological conditions, including pain and inflammation. At the central nervous system, the role of Panx1 is already well-established. However, in the periphery, there is a lack of information regarding the participation of Panx1 in neuronal sensitization. The dorsal root ganglion (DRG) is a critical structure for pain processing and modulation. For this reason, understanding the molecular mechanism in the DRG associated with neuronal hypersensitivity has become highly relevant to discovering new possibilities for pain treatment. Here, we aimed to investigate the role of Panx1 in acute nociception and peripheral inflammatory and neuropathic pain by using two different approaches.
METHODS: Rats were treated with a selective Panx1 blocker peptide (10Panx) into L5-DRG, followed by ipsilateral intraplantar injection of carrageenan, formalin, or capsaicin. DRG neuronal cells were pre-treated with 10Panx and stimulated by capsaicin to evaluate calcium influx. Panx1 knockout mice (Panx1-KO) received carrageenan or capsaicin into the paw and paclitaxel intraperitoneally. The von Frey test was performed to measure the mechanical threshold of rats' and mice's paws before and after each treatment.
RESULTS: Pharmacological blockade of Panx1 in the DRG of rats resulted in a dose-dependent decrease of mechanical allodynia triggered by carrageenan, and nociception decreased in the second phase of formalin. Nociceptive behavior response induced by capsaicin was significantly lower in rats treated with Panx1 blockade into DRG. Neuronal cells with Panx1 blockage showed lower intracellular calcium response than untreated cells after capsaicin administration. Accordingly, Panx1-KO mice showed a robust reduction in mechanical allodynia after carrageenan and a lower nociceptive response to capsaicin. A single dose of paclitaxel promoted acute mechanical pain in wildtype (WT) but not in Panx1-KO mice. Four doses of chemotherapy promoted chronic mechanical allodynia in both genotypes, although Panx1-KO mice had significant ablation in the first eight days.
CONCLUSION: Our findings suggest that Panx1 is critical for developing peripheral inflammatory pain and acute nociception involving transient receptor potential vanilloid subtype 1 (TRPV1) but is not essential for neuropathic pain chronicity.
BACKGROUND: Femoroacetabular impingement (FAI) is a condition where the femoral head-neck junction collides with the acetabulum. Open or arthroscopic treatment of FAI aims to increase hip motion while reducing impingement during passive or dynamic movements.
RESEARCH QUESTION: What are the biomechanical characteristics of the hip and pelvis in adolescents and young adults diagnosed with FAI syndrome 1) pre-operatively compared to controls and 2) pre- to post-operatively?
METHODS: 43 patients with FAI and 43 controls were included in the study. All patients with FAI had cam deformities and underwent unilateral hip preservation surgery (either open or arthroscopic). Pre- and post-operative imaging, patient-reported outcomes, and gait analysis were performed. Joint angles and internal joint moments were evaluated with an emphasis on the pelvis and hip. A comparative analysis was conducted to evaluate the gait patterns before and after surgical treatment, as well as to compare pre-operative gait patterns to a control group.
RESULTS: 43 patients with FAI (28 female, 16.5 ± 1.5 yrs) and 43 controls (28 female, 16.0 ± 1.5 yrs) were included. Pre-operative patients with FAI had decreased stride length and walking speed compared to controls, with no significant change following surgery. There were no differences in sagittal and coronal plane hip and pelvis kinematics comparing pre- to post-operative and pre-operative to controls. Pre-operatively, differences in internal hip rotation angle (pre: 3.3˚, post: 3.9˚, controls: 7.7˚) and hip extensor moment (pre: 0.121, post: 0.090, controls: 0.334 Nm/kg) were observed compared to controls with no significant changes observed following surgery.
SIGNIFICANCE: Compensatory movement strategies in pelvic and hip motion are evident during gait in patients with FAI, particularly in the sagittal and transverse planes. These strategies remained consistent two years post-surgery. While surgery improved radiographic measures and patient-reported outcomes, gait did not elicit biomechanical changes following surgical treatment.
Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, Fisetin has the best safety profile. Hence, the investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with PAD. The investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with PAD. In exploratory analyses, the investigators will assess whether Fisetin reduces IL-6 and novel senescent markers in adipose tissue, muscle, and/or blood.

To achieve the trial's specific aims, investigators will randomize 34 participants age 50 and older with PAD to one of two groups: Fisetin vs placebo. Participants will be followed for four months.
Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
Approximately 75% of breast cancers express the estrogen and/or progesterone receptor (hormone receptors). The standard of care for women with hormone receptor positive breast cancer is five to ten years of adjuvant endocrine therapy with drugs such as tamoxifen or aromatase inhibitors (AIs). In women with stage I-III breast cancer, treatment with adjuvant endocrine therapy has been shown to reduce recurrences by 30-50% and improve survival. Unfortunately, it is estimated from large population databases that up to 35-40% of patients may discontinue adjuvant endocrine therapy before completing the recommended 5 years for various reasons, and non-adherence may reduce survival.

The current protocol is a pilot study in women with hormone receptor positive breast cancer who are beginning adjuvant endocrine therapy, the purpose of which is to assess the feasibility of a two-way text messaging application, with goals for a larger randomized control study to assess if the application will increase adherence and therefore improve disease free survival. This application includes daily text message medication reminders and periodic assessment of side effects and barriers to medication adherence and simultaneously offers assistance for treatment related issues. The investigators will collect information on QOL and financial burden during the 3 month period and will correlate these metrics with adherence. This larger randomized control study would be the first such interventional study to increase adherence with adjuvant endocrine therapy in breast cancer in the US. Our larger randomized control trial would provide the first longitudinal prospectively collected information on QOL, financial burden and adherence over the entire 5-year treatment period in the routine clinical practice setting.
PURPOSE: A fermented placental composition is provided to enhance high amino acid content and to be used as an ingredient for cosmetic products and food. CONSTITUTION: A method for making a fermented placental composition comprises: a step of crushing mammal placenta; a step of adding 3-30 weight parts of carbon source and energy source of microorganism and mixing; and a step of inoculating lactobacillus, yeast, or bacillus into the mixture and fermenting. The carbon source and energy source of microorganism is oligosaccharide, lactose, glucose, fructose, sugar, or mixture thereof. The lactobacillus is Lactobacillus sp., Streptococcus sp., Pediococcus sp., Leuconostoc sp., or Bifidobacterium sp. The yeast is Saccharomyces sp. A composition for treating atopic dermatitis contains the fermented placental composition as an active ingredient.
PURPOSE:The titled pharmaceutical of a slightly soluble drug consisting of the slightly soluble drug, a release inhibitor and high swelling polymer. CONSTITUTION:A sustained release pharmaceutical containing a slightly soluble drug, e.g. isosorbid nitrate, prazosin hydrochloride or furosemide, 5-80wt% release inhibitor, e.g. ethyl cellulose, acrylic acid-methacrylic ester copolymer, hardened oil or wax and 0.5-20wt% swelling high polymer, e.g. carboxyvinyl polymer, hydroxypropyl cellulose with a low substitution degree or microcrystalline cellulose. The resultant pharmaceutical has a little change in release rate due to variation in size of granular material, method of preparation, hardness of compression molded material, etc., and therefore excellent reproducibility of release rate renders the pharmaceutical suitable for mass production. The slightly soluble drug is released for a long time by given combination of the above-mentioned respective materials, and the dissolution rate of the slightly soluble drug shows a safe dissolution of about 100%.
Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.